MET and metastatic neoplasm: However, MET amplification appears at a very low percentage in different breast cancer data sets both in primary (TCGA BRCA (0.4%), (Pereira et al, 2016) (1.5%), (Razavi et al, 2018) (0.1%)) and metastatic tumours (2.3%) (Lefebvre et al, 2016), MBC project 2018 (1.3%), (0.2%) (Zehir et al, 2017), (0.15%) (Razavi et al, 2018).